ホームページへ

仕組みについて

クリニック検索プロセスを変革し、シンプル、高速、パーソナルにしました。
いくつかの質問に回答お客様の症状と医療ニーズについて短いフォームにご記入ください。
パーソナライズオファーを取得お客様の回答に基づいて厳選された3つのクリニックがカスタマイズされた治療計画と見積もりを提供します。
最良のオプションを選択オファーを比較して最適なクリニックをお選びください。
また、以下の2軒のクリニックすべてをご覧いただけます
820К+ 2014年以降患者がサポートを受けています
50
1,500 クリニック
6K+ レビュー
3K+ 3,000名以上の資格を持つ医師

中国での食道癌診断・治療費用について今すぐご確認ください

料金はお問い合わせください
中国トルコオーストリア
食道癌化学療法から $12,500から $5,000から $12,000
食道摘出術から $18,500から $23,400から $30,000
放射線治療から $14,500から $7,000から $20,000
大腸癌に対する放射線療法から $11,500から $7,000から $12,000
乳癌化学療法から $14,800から $1,200から $15,000
データは2026年July月時点でBookimedにより検証され、世界148件のクリニックからの患者リクエストと公式見積もりに基づいています。中央値費用は実際の請求書(2024年-2026年)に基づいており毎月更新されます。実際の価格は異なる場合があります。

中国で食道癌の医学評価を受ける:今すぐ経験豊富な医師にご相談ください

すべての医師を見る
検証済み

Liu Shi Xin

40年の経験

Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.

  • Highly proficient in IMRT, VMAT, and SBRT for lung and esophageal cancers.
  • Former President of Jilin Provincial Cancer Hospital.
  • Awarded the National Famous Doctor honor for outstanding contributions to oncology.
  • Holds leadership roles in the Chinese Anti-Cancer Association particle therapy committee.

このコンテンツを共有

Bookimed患者のビデオストーリー

Dayana
I combined my vacation in Antalya with a check-up.
治療: 女性検査
クリニック: Memorial Antalya Hospital
Igor
It was great! Transfers, accommodation, treatment—all included.
治療: 歯科インプラント
クリニック: WestDent Clinic
Marina
Bookimed did everything for me. I didn't have to worry about anything.
治療: 女性検査
クリニック: Severance Hospital
更新済み: 05/28/2026
著者
アンナ・レオノヴァ
アンナ・レオノヴァ
コンテンツマーケティングチーム責任者
10年以上の経験を持つ認定医療ライターで、文学修士号を持ち、世界中の医療専門家のインタビューに基づくBookimedの信頼できるコンテンツを開発しています。
Fahad Mawlood
医学編集者・データサイエンティスト
一般開業医。4つの科学賞受賞。西アジアでの勤務経験。アラビア語を話す患者様をサポートする医療チームの元チームリーダー。現在はデータ処理と医療コンテンツの正確性を担当
Fahad Mawlood Linkedin
このページは、さまざまな国で利用可能な各種医療状態、治療、ヘルスケアサービスに関する情報を掲載する場合があります。コンテンツは情報提供のみを目的として提供されており、医療アドバイスやガイダンスとして解釈されるべきではないことをご承知おきください。医療治療を開始または変更する前に、医師または資格のある医療専門家にご相談ください。

中国での食道癌治療に関するFAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

What is the standard treatment approach for locally advanced esophageal cancer in China?

China treats locally advanced esophageal cancer with a multidisciplinary approach combining neoadjuvant therapy and radical surgery. Over 90% of cases are squamous cell carcinoma. Standard care involves preoperative chemotherapy, chemoradiation, or immunotherapy to downstage tumors. Surgeons then perform esophagectomy with extensive lymph node dissection.

  • Neoadjuvant therapy: Platinum-taxane chemotherapy or immunotherapy boosts pathological complete response rates.
  • Surgical approach: The McKeown right thoracic procedure permits comprehensive lymph node clearance.
  • Radiotherapy precision: Doctors utilize IMRT and VMAT to target tumors while sparing organs.
  • Inoperable cases: Definitive chemoradiotherapy serves as the primary standard for unresectable tumors.

Bookimed Expert Insight: Chinese oncology centers demonstrate high proficiency in treating squamous cell carcinoma due to high domestic volumes. Fuda Cancer Hospital manages over 30,000 international patients. Specialized professors like Dr. Liu Shi Xin at Xiamen Humanity Hospital focus specifically on precision radiotherapy. This specialization often translates into more aggressive lymph node clearance protocols compared to Western clinics.

Patient Consensus: Patients emphasize that managing weight loss and nutrition is as vital as the cancer treatment itself. Many note that recovery after surgery is a long process requiring significant dietary adjustments.

What role does immunotherapy play in advanced esophageal cancer treatment in China?

Immunotherapy is the modern cornerstone for advanced esophageal cancer in China. It serves as primary first-line care for metastatic cases. Chinese protocols combine PD-1 inhibitors with chemotherapy to improve survival. This approach targets esophageal squamous cell carcinoma which is highly prevalent in the region.

  • First-line therapy: Combines PD-1 inhibitors with chemotherapy for untreated metastatic disease.
  • Survival outcomes: Clinical trials like JUPITER-06 show survival extending to 17 months.
  • Second-line use: Immunotherapy monotherapy provides superior survival over traditional second-line chemotherapy.
  • Neoadjuvant setting: Pre-surgical immunotherapy helps downstage tumors in locally advanced cases.

Bookimed Expert Insight: While many global patients focus on brand-name drugs, JCI-accredited centers like Fuda Cancer Hospital utilize a massive volume of specialized domestic PD-1 inhibitors. These centers manage over 30,000 international patients. This high volume allows Chinese oncologists to refine combination protocols specifically for squamous cell carcinoma. They often integrate immunotherapy with specialized local treatments like microwave hyperthermia or cryosurgery.

Patient Consensus: Patients emphasize that biomarker testing for PD-L1 is a vital first step for eligibility. Many note that while daily side effects feel milder than chemo, they watch closely for sudden immune-related fatigue or rashes.

Are minimally invasive surgeries common in Chinese hospitals?

Minimally invasive surgery is widely available in Chinas premier hospitals and specialized centers. These institutions utilize robotic systems and advanced endoscopy for complex cases. High patient volumes allow surgical teams to refine these precision techniques. Some centers report significant results for late-stage cancer care.

  • Available technologies: Centers use NanoKnife, cryosurgery, and vascular interventional therapy.
  • Specialized facilities: Fuda Cancer Hospital serves over 30,000 patients from 100 countries.
  • Accreditation standards: Top-tier oncology hospitals maintain Joint Commission International (JCI) accreditation.
  • Surgical expertise: Professors like Dr. Liu Shi Xin specialize in precision thoracic procedures.

Bookimed Expert Insight: Specialized oncology hospitals in China like Fuda Cancer Hospital frequently focus on over 10 different types of minimally invasive therapies. This variety suggests that Chinese centers often combine multiple localized treatments rather than relying on a single surgical approach. This strategy is particularly common for advanced or late-stage cancer cases.

Patient Consensus: Patients value the shorter recovery times of minimally invasive methods but emphasize checking a surgeons specific case volume. While robotic options are available, many note that preoperative planning is more critical than the technology used.

How accessible are cutting-edge clinical trials for esophageal cancer in China?

Cutting-edge clinical trials for esophageal cancer in China are highly accessible for patients at major academic centers. China manages over 50% of global cases. This high volume accelerates patient recruitment. Research institutions utilize specialized networks to match candidates with advanced protocols efficiently.

  • Therapeutic focus: Trials prioritize next-gen immunotherapy and CAR-T cell therapies for solid tumors.
  • Technology access: Centers use IMRT, VMAT, and SBRT alongside experimental neoadjuvant drug combinations.
  • Regulatory speed: Investigator-initiated trials allow elite hospitals to launch studies before formal commercial approval.
  • Diagnostic precision: Programs integrate PET/CT, genomic screening, and biopsy to confirm specific protocol eligibility.

Bookimed Expert Insight: Data suggests that centralized care in cities like Guangzhou or Xiamen is vital for trial entry. JCI-accredited facilities like Fuda Cancer Hospital serve over 30,000 international patients. Experienced specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital coordinate complex precision radiotherapy. Patients should target these high-volume tertiary hospitals rather than local clinics to find active enrollment opportunities.

Patient Consensus: Patients note that trial windows move very fast during the staging process. They emphasize having all pathology and imaging reports translated before reaching out to major urban centers.

Can Traditional Chinese Medicine (TCM) be integrated into my cancer treatment?

Traditional Chinese Medicine (TCM) integrates with conventional esophageal cancer treatment as a supportive therapy. It manages side effects from chemotherapy or radiation. Practitioners use acupuncture for nausea and pain. Herbal medicine may protect liver function. Patients must prioritize surgery or chemoradiation over traditional remedies.

  • Treatment focus: TCM restores biological balance and boosts immunity during standard oncology.
  • Acupuncture benefits: Specialists use it to reduce chemotherapy-induced nausea and cancer-related fatigue.
  • Herbal safety: Herbs can interfere with oncology drugs or cause surgical bleeding.
  • Oncology integration: JCI-accredited facilities like Fuda Cancer Hospital combine minimally invasive therapies.

Bookimed Expert Insight: Leading Chinese centers like Fuda Cancer Hospital serve over 30,000 international patients. They often replace standard systemic chemotherapy with over 10 types of minimally invasive therapies. These include cryosurgery and vascular interventional therapy. If you seek TCM, choose hospitals with these advanced technologies. They provide a more controlled environment for integrative care than standalone herbal clinics.

Patient Consensus: Patients note that TCM helps with appetite and fatigue but warn against using it alone. Many emphasize that delaying standard treatment for herbal cures often leads to regret as the cancer progresses.

無料相談を受ける

最適な連絡方法をお選びください